drugset / Trial / NCT07583511

Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study

NCT07583511

Phase 2 Recruiting 90 enrolled Sun Yat-sen University
RandomizedParallel-groupOpen-labelTreatment

Summary

To compare the efficacy and safety between teniposide, cisplatin and serplulimab regimen and etoposide, cisplatin and serplulimab regimen in the treatment of extensive stage small lung cancer

Timeline

Start
2024-02-01
Primary completion
2027-05-01
Completion
2027-12-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Etoposide Small molecule
Subject Teniposide Small molecule
Background Cisplatin Other / unclassified
Background Serplulimab Monoclonal antibody